As of 2025-07-12, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 13.8x | 13.6x |
| Forward P/E multiples | 19.5x - 20.5x | 20.0x |
| Fair Price | (13.83) - (9.65) | (11.83) |
| Upside | -121.3% - -114.8% | -118.2% |
| Date | EV/EBITDA |